Enabling you to identify and mitigate the intrinsic risk in your operations, supply chains and business processes.
Evaluating how your products and services meet and exceed quality, safety, sustainability and performance standards.
Validating the specifications, value and safety of your raw materials, products and assets.
Register now for our webinar: Advanced analytical techniques for the testing of orally inhaled and nasal drug products; how to build confidence in the in-vitro data for your generic product.
Our expert, Chris Vernall, Business Development Director, will present this webinar. During the session Chris will cover:
15 Feb 2018 | 16:00 CET | 15:00 GMT | 10:00 EST
About Intertek's Inhalation Development Services
Intertek’s integrated development capabilities include formulation and analytical experts undertake early stage pre-formulation support, formulation development, inhalation product analysis and testing, solubility screening, drug-excipient compatibility, stability testing and device selection support to aid clients working to develop formulations targeting specific regions of the respiratory tract or nasal cavity.
About our expert
Chris is currently the Business Development Director at Intertek Melbourn. He is an analytical chemist by training and holds a Master’s Degree from Loughborough University.
Chris started his career at Pfizer, as a Materials Scientist working on novel inhaled compounds, before moving to Nanopharm where he worked in formulation, specifically with DPIs and pMDIs.
He then made the move to Intertek Melbourn as a Senior Analyst, before taking up the role of Business Development Manager in 2014. He started in his Director role in April of this year.